This is in accordance with a study performed in a gastric cancer cell line [25], and other studies using different tumor models, namely gliomas, colorectal cancer and melanomas, where SOX2 was associated with disease progression and poor clinical outcome [26–28]. This evidence concerns the gene SOX2 and glioma.